

Rabbit Anti-NCOA2/SRC2 Polyclonal: RC0158-0.2ML

Intended Use: For Research Use Only

Description: NCOA2 (Nuclear receptor coactivator 2) (also known as SRC2, BHLHE75, GRIP1, KAT13C, TIF2), is a 160 kDa transcriptional coactivator for steroid receptors and nuclear receptors that acts as a coactivator of the steroid binding domain (AF-2), but not the modulating N-terminal domain (AF-1). It possesses a single NR interaction domain (NID) and two autonomous activation domains, AD1 and AD2. NCOA2 assists nuclear receptors in the upregulation of DNA expression. In cells ligand activated nuclear receptors recruit NCOA2 to DNA where it acylates histones to make targeted regions accessible to transcriptional machinery. Along with NCOA1 it controls energy balance between white and brown adipose tissues and also acts as a critical regulator of glucose metabolism. It is also involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3. NCOA2 is reported to positively regulate the circadian clock by acting as a transcriptional coactivator for the CLOCK-ARNTL/BMAL1 heterodimer. Chromosomal aberrations involving NCOA2 may be a cause of acute myeloid leukemias.

Specifications


Clone:	Polyclonal
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human, mouse, rat
Immunogen:	Synthesized peptide aa 702-751 of human NCOA2
Localization:	Nucleus
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA
Package:	

Description	Catalog No.	Size
NCOA2/SRC2 Polyclonal Concentrated	RC0158-0.2ML	0.2 ml

IHC Procedure*

Positive Control Tissue:	Kidney, breast carcinoma, prostate adenocarcinoma
Concentrated Dilution:	25-100
Pretreatment:	Citrate pH6.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	Overnight @ 4°C
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human esophageal cancer stained with anti-NCOA2 using DAB

References:

1. Clinicopathologic and genetic characterization of angiofibroma of soft tissue: a study of 12 cases including two cases with AHRR::NCOA3 gene fusion. Kyoko Yamashita, et al. Histopathology. March, 2023.
2. Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Elise M Bekers, et al. Genes Chromosomes Caner. June 2017.
3. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. Maria P. Silva. Et al. Genes Chromosomes Caner. January 2016.